Analysts Offer Insights on Healthcare Companies: Ra Medical Systems Inc (NYSE: RMED), Dermira (NASDAQ: DERM) and BioLife Solutions (NASDAQ: BLFS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ra Medical Systems Inc (RMEDResearch Report), Dermira (DERMResearch Report) and BioLife Solutions (BLFSResearch Report) with bullish sentiments.

Ra Medical Systems Inc (RMED)

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Ra Medical Systems Inc today and set a price target of $15. The company’s shares closed yesterday at $6.57, close to its 52-week low of $6.

Vendetti noted:

“Market close, RMED reported lower-than-expected 4Q18 results, including lower Vascular revenue and significantly higher operating expenses. RMED signed 19 new DABRA usage agreements in the quarter, bringing the total to 53 agreements. Given production issues, which were recently resolved, the company provided 1Q19 revenue guidance of $1.0M-$1.4M, including Vascular revenue of $0.3M- $0.4M, which was well-below our estimate and consensus. As a result, we are lowering our estimates and price target to $15, from $23.”

According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 6.1% and a 49.6% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Sensus Healthcare Inc.

Ra Medical Systems Inc has an analyst consensus of Moderate Buy, with a price target consensus of $11, which is a 67.4% upside from current levels. In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $11 price target.

See today’s analyst top recommended stocks >>

Dermira (DERM)

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Dermira today and set a price target of $20. The company’s shares closed yesterday at $6.91, close to its 52-week low of $6.00.

Chen observed:

“DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $20.”

According to TipRanks.com, Chen is a 5-star analyst with an average return of 13.6% and a 41.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.

Currently, the analyst consensus on Dermira is a Moderate Buy with an average price target of $15.75, a 127.9% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $13 price target.

BioLife Solutions (BLFS)

Maxim Group analyst Jason McCarthy maintained a Buy rating on BioLife Solutions today and set a price target of $24. The company’s shares closed yesterday at $17.69.

McCarthy said:

“BioLife reported 4Q18 with $5.5M in revenue, up 74% y/y and 3% sequentially, with reported gross margin of 69%. BioLife also reported a $0.8M net profit for the quarter, and $3.2M for the year, marking the first profitable full year, which in our view is a significant accomplishment. The company ended the period with $30.7M in cash.”

According to TipRanks.com, McCarthy is a 3-star analyst with an average return of 1.7% and a 34.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Inovio Pharmaceuticals, and Vertex Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioLife Solutions with a $18 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Leave a Reply

Your email address will not be published. Required fields are marked *